Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 04, 2026 07:30 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial Vancouver, Canada, March 04, 2026 (GLOBE...
February 09, 2026 08:17 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Vancouver, Canada, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery...
January 14, 2026 08:55 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

Vancouver, Canada, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery...
December 01, 2025 08:56 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial

Vancouver, Canada, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
November 10, 2025 08:07 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Milestone advances MEAI-based therapy targeting a global Alcohol Use Disorder treatment market projected to surpass $20 billion by 2032 Vancouver, Canada, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ...
October 21, 2025 07:25 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Vancouver, Canada, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
June 27, 2025 09:00 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market

Vancouver, Canada, June 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
June 23, 2025 07:55 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder

Vancouver, Canada, June 23, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
April 10, 2025 08:25 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder

Vancouver, Canada, April 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
March 13, 2024 08:14 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a clinical- stage biotech company focused on discovery...